Since its recent approval by the United States Food and Drug Administration, fluciclovine PET-CT has gained widespread use for imaging of recurrent prostate cancer patients. As an amino acid–based radiotracer transported by LAT-1 and ASCT-2 transporters, fluciclovine exploits the up-regulation of amino acid transporters in malignant cells. We present a rare case of fluciclovine uptake in Paget disease in a 58-year-old man with suspected recurrent prostate cancer and asymmetric increased left hemipelvic uptake on imaging.
From the *Division of Nuclear Medicine and Molecular Imaging, Department of Radiology and Imaging Sciences, Emory University
†Veterans Administration Medical Center, Atlanta, Georgia.
Received for publication March 16, 2019; revision accepted May 3, 2019.
Conflicts of interest and sources of funding: none declared.
Correspondence to: Oladunni Akin-Akintayo, MD, MPH, Division of Nuclear Medicine, Department of Radiology and Imaging Sciences, Emory University School of Medicine, 1364 Clifton Rd, Atlanta, Georgia 30322. E-mail: firstname.lastname@example.org.
Online date: July 8, 2019